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Abstract In vitro evidence has suggested a change in the ability
of tau bearing mutations associated with fronto-temporal
dementia to promote microtubule assembly. We have used a
cellular assay to quantitate the effect of both isoform differences
and mutations on the physiological function of tau. Whilst all
variants of tau bind to microtubules, microtubule extension is
reduced in cells transfected with 3-relative to 4-repeat tau.
Mutations reduce microtubule extension with the P301L
mutation having a greater effect than the V337M mutation.
The R406W mutation had a small effect on microtubule
extension but, surprisingly, tau with this mutation was less
phosphorylated in intact cells than the other variants.
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1. Introduction
Abnormal accumulations of the microtubule associated
protein tau in paired helical or straight ¢laments characterise
a number of neurodegenerative conditions including Alzheim-
er’s disease, progressive supranuclear palsy and fronto-tempo-
ral degeneration [1]. The process whereby tau becomes depos-
ited in these structures is not understood although evidence
points to an early increase in phosphorylation in AD (re-
viewed in [2]). Linkage of a form of fronto-temporal degen-
eration to chromosome 17 (FTDP-17) was followed by the
identi¢cation of mutations in the tau gene in a number of
families [3^8].
The tau gene is alternatively spliced to produce six isoforms
in adult human brain di¡ering by possession of three or four
microtubule binding domains and one or two amino-terminal
inserts of unknown function. Some missense mutations asso-
ciated with FTDP-17 are localised in the microtubule binding
domain, whilst another (R406W) is in the adjacent C-terminal
region. The intronic mutations have been shown to result in
an increase in generation of isoforms with four microtubule
binding domains probably because of an alteration in second-
ary structure of the splice donor site following exon 10 [5,6].
It has been suggested that an imbalance in the relative pro-
portion of tau with either three or four microtubule binding
domain repeats could lead to an excess of 4-repeat tau which
may then aggregate [9]. As the missense mutations localise
either within or adjacent to the critical microtubule binding
domain, a prime hypothesis for the pathogenic e¡ect of these
mutations was a reduction in the ability of tau to bind micro-
tubules resulting in the abnormal accumulation of tau and
microtubule instability. Evidence in favour of this hypothesis
was provided by in vitro studies demonstrating a reduction in
the ability of tau to promote microtubule assembly [10,11].
However, this e¡ect was most marked in the ¢rst few minutes
of tubulin polymerisation and all tau variants increase micro-
tubule assembly substantially after 10 min. Given that the
observed loss of function of tau demonstrated in these studies
was partial only, it remained possible that the mutations
would not substantially a¡ect this property of tau in situ. In
order to establish whether the in vitro observations translate
to di¡erences in situ, we have characterised the ability of
di¡erent tau variants to promote microtubule extension in
intact cells.
2. Materials and methods
2.1. Cell culture and transfection
CHO cells were cultured in K-MEM supplemented with 10% (v/v)
foetal calf serum, 2 mM glutamine, 100 IU/ml penicillin and 100 Wg/
ml streptomycin (all Gibco BRL). Human SHSY5Y neuroblastoma
were cultured in DMEM/F12 supplemented with 10% (v/v) foetal calf
serum and di¡erentiated with staurosporine (20 nM). Human BE(2)-
M17 neuroblastoma were grown in OPTI-MEM (Life Technologies)
supplemented with 2.4 g/l sodium bicarbonate (Mallinckrodt Baker),
2 mM L-glutamine (Sigma) and 10% foetal bovine serum (Life
Technologies). CHO and SHSY5Y cells were transiently transfected
using Lipofectamine reagent (Gibco BRL) and BE(2)-M17 cells with
Tfx-20 reagent (Promega), both according to the manufacturer’s
recommendations.
2.2. Expression of tau variants
Site-directed mutagenesis (Promega Gene Editor) was used to in-
troduce a series of missense mutations (V337M, R406W and P301L)
in human tau (exon 1, 4, 5, 7, 9, 11^13) containing 3 or 4 microtubule
binding domain repeats (but without an NH2-terminal insert)




TATC-3P. The di¡erent tau constructs were then ampli¢ed with the
Expand High Fidelity Kit (Boehringer Mannheim) using primers with
BglII and SalI linkers (ACTCAGATCTAGGATGGCTGAGCC and
CCCAGTCGACTGATCACAAACCCT) for directional restriction
site cloning into pEGFP (Clontech). All constructs were veri¢ed by
sequencing. Untagged constructs were recloned into the SalI site of
pcDNA3.1(+) (Invitrogen).
2.3. Microscopy
To examine the co-localisation of tau and microtubules, SHSY5Y
cells were rinsed with PBS and then incubated with 0.3% (v/v) glutar-
aldehyde in PBS for 10 min at room temperature before permeabili-
sation with 0.5% (v/v) Triton in PBS. Coverslips were treated with
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sodium borohydride (10 mg/ml, Sigma) in PBS for 10 min, incubated
with 0.1 M glycine in PBS for 20 min and then blocked with 5% (v/v)
horse serum in PBS for 30 min. A primary monoclonal antibody
against alpha-tubulin (DM1A, 1:100, Sigma) was followed by a sec-
ondary Texas red-conjugated secondary antibody (Molecular Probes).
In other experiments, M17 cells were rinsed with stabilisation bu¡er
(SB) containing 80 mM PIPES, 30% glycerol, 1 mM MgCl2, 1 mM
EGTA and 1.1 mM GTP, and ¢xed for 15 min at room temperature
in 2% (v/v) paraformaldehyde/0.1% (v/v) glutaraldehyde/SB. The ¢xed
cells were exposed in sequence to methanol, sodium borohydride (1
mg/ml in PBS) and glycine (100 mM in PBS) prior to permeabilisation
with 0.3% (v/v) Triton X-100/PBS. A blocking step in 3% (v/v) goat
serum/0.1 M Tris saline (pH 7.6) preceded the incubation with a
primary monoclonal antibody to beta-tubulin (clone TUB2.1, 1:100
dilution, Sigma) and a secondary rhodamine-conjugated goat anti-
mouse IgG antibody (Zymed Laboratories). Fixed cells were visual-
ised either using a Zeiss light microscope and Pentamax (Princeton
instruments) camera or an Olympus Fluoview Confocal Laser Scan-
ning Microscope.
2.4. Microtubule extension assay
CHO cells were transfected with 1 Wg of cDNA encoding tau-EGFP
variants and cultured at low density on coverslips overnight before
treatment with 20 WM cytochalasin B (Sigma) for a further 24 h. Cells
were carefully ¢xed with 4% (w/v) paraformaldehyde for 30 min so as
to minimise disruption to processes. For analysis of microtubule ex-
tension formation, transfected cells were observed by £uorescence
microscopy (Zeiss) and images acquired using a Pentamax camera
(Princeton Instruments). For each tau variant, 50 images were taken
entirely at random. The ¢rst 100 consecutive cells were analysed using
MetaMorph software (Universal Imaging) both by counting the num-
ber of tau-¢lled cell processes and by measuring the length of each
process. All experimentation and analysis was performed entirely
blind. For statistical analysis the data from two separate experiments
were combined and tau variant data were compared using ANOVA
and the t-test for independent samples.
2.5. SDS-PAGE and immunoblotting
For analysis of tau phosphorylation, tau was isolated from CHO
and COS cells transiently transfected with untagged tau constructs.
Heat stable tau was harvested as previously described [12] and sub-
jected to 10% (v/v) SDS-PAGE. Blots were incubated with primary
antibodies at 4‡C overnight and subsequently developed by enhanced
chemiluminescence (ECL, Amersham). Antibodies used included the
phosphorylation-independent rabbit polyclonal TP70 (1/10 000, [13]),
and the phosphorylation-dependent mouse monoclonals recognising
tau phosphorylated at Ser-202 and Thr-205 (AT8, 1/200, [14]), tau
not phosphorylated at an overlapping epitope, Ser-199 and Ser-202
(Tau 1, 1/200 [15]) and tau phosphorylated at an epitope close to the
R406W mutation Ser-396 and Ser-404 (PHF1, 1/200, [16])
3. Results
3.1. Mutated tau binds microtubules in non-neuronal and in
neuronal cells
When expressed in transfected cells, tau binds microtubules
and promotes the formation of microtubule bundles [17]. In
order to establish ¢rst whether this property of tau is abol-
ished by mutations associated with neurodegeneration, we
transiently transfected a non-neuronal cell line (CHO) and
human neuroblastoma cells (M17 and SHSY5Y) with wild-
type 4-repeat and 3-repeat EGFP-tau and EGFP-tau with
R406W, V337M and, in the case of 4-repeat, P301L muta-
tions. Microtubules were labelled by immunostaining using
primary antibodies to tubulin. In all transiently transfected
cell lines there was no obvious qualitative di¡erence between
wild-type and mutated tau or between 4-repeat and 3-repeat
isoforms. In each case, tau bound microtubules and induced
the formation of tau-decorated microtubule bundles which, in
neuroblastoma but not in non-neuronal cells, tended to ¢ll
neurite-like extensions (Fig. 1).
3.2. E¡ects of tau variants on the ability of tau to promote
microtubule polymerisation in cells
In non-neuronal cells, expression of tau induces a rear-
rangement of the normal cytoskeleton with long, straight mi-
crotubules dissociated from the normal microtubule organis-
ing centre and microtubule bundles arranged around the
periphery of the cell [18]. Other MAPs have similar e¡ects
and it has been previously demonstrated that if the actin cy-
toskeleton is disrupted by cytochalasin B, these sti¡ micro-
tubule bundles push extensions out of the cell and thereby
assume some of the properties of neuritic extensions [19].
We used this approach to quantitate the e¡ects of tau variants
on microtubules (Fig. 2). Measurements of microtubule exten-
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Fig. 1. Tau with and without mutations binds to microtubules.
SHSY5Y neuroblastoma cells (A^F) and M17 neuroblastoma cells
(G, H) transfected with wild-type 4-repat tau (A, B), R406W mu-
tant tau (C, D) and P301L mutant tau (E^H). In all cases, tau was
visualised with the EGFP tag (A^G) and microtubules with the
antibody DM1A recognising tubulin. SHSY5Y cells were examined
with light microscopy and M17 cells with confocal microscopy.
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sions were made on a total of 1400 cells (2728 separate cell
extensions, Fig. 3). The wild-type 4-repeat tau induced more
extensions than the wild-type with only 3 repeats (mean 2.04
compared to 1.50; S.D. 2.0 and 1.4; Independent t-test val-
ue = 3.11; P6 0.005). We then compared the sum of the
length of extensions per cell ¢nding a longer mean extension
length in 4-compared to 3-repeat tau (ANOVA P6 0.05). Of
the tau mutants, the greatest e¡ect was found for the P301L
mutation, which reduced the extension length of 4-repeat tau
by 33.8% (from 39 Wm to 26 Wm; ANOVA, P6 0.005). The
R406W mutation did not appear to signi¢cantly a¡ect the
mean extension length for either 3- or 4-repeat tau whilst
the V337M reduced the extension length in both cases by
17%. This consistent reduction in extension length, caused
by the mutation, just failed to reach signi¢cance when consid-
ering the di¡erent isoforms separately (ANOVA; P = 0.06 for
3-repeat and P = 0.08 for 4-repeat). However combining iso-
forms (V337M or R406W 3- and 4- repeat compared to wild-
type 3- and 4-repeat), a signi¢cant reduction in extension
length was seen for both mutations, albeit larger and more
signi¢cant for the V337M variant (37 Wm versus 30 Wm for
V337M; ANOVA P6 0.01; 37 Wm versus 34 Wm for R406W
ANOVA P6 0.05).
3.3. E¡ects of mutations on the phosphorylation of tau by
endogenous kinases and by GSK-3L
In order to examine the e¡ects of the mutations on tau
phosphorylation, tau with both three and four microtubule
binding domains was transiently expressed in CHO cells. As
in previous studies [20] three bands recognised by the phos-
phate-independent antibody TP70 were apparent following
SDS-PAGE (Fig. 4, only 4-repeat data shown). All three
bands were recognised by an antibody TAU1, recognising
tau not phosphorylated at Ser-199/202, which also labelled a
very faint faster migrating band, possibly a degradation prod-
uct. None of the species identi¢ed by TP70 or TAU1 were
recognised by AT8 but another phosphorylation-dependent
antibody, PHF-1, did faintly label tau in these cells. As pre-
viously reported [12], when co-transfected with cDNA encod-
ing glycogen synthase kinase-3L (GSK-3L) one or two bands
of wild-type tau are labelled with TP70 and the slowest mi-
grating band of this pair is recognised by phosphorylation-
dependent antibodies such as AT8 raised to epitopes of tau
that are phosphorylated in AD. TAU-1 immunoreactivity was
decreased in the co-transfected cells and PHF-1 immunoreac-
tivity was increased.
We then expressed 3-repeat tau with the V337M and
R406W mutations and 4-repeat tau with V337M, R406W
and P301L mutations alone and in co-transfection experi-
ments with GSK-3L. In co-transfection experiments, all var-
iants of tau were indistinguishable from wild-type tau in both
the migration pattern and immunoreactivity indicating that all
were similarly phosphorylated by GSK-3L overexpression. In
the absence of GSK-3L, the variants of tau possessing V337M
and P301L mutations were also indistinguishable from wild-
type tau but both 3- and 4-repeat tau with the R406W muta-
tion resolved as a single band co-migrating with the fastest
migrating band of wild-type tau (Fig. 4, only 4-repeat data
shown). Repeated transfection experiments gave identical re-
sults. This single band of 3-repeat R406W and 4-repeat
R406W tau was recognised by TP70 and TAU1 but not by
AT8 and PHF-1 indicating that it was not phosphorylated at
the epitopes identi¢ed by these antibodies. Notably, a band of
wild-type tau and P301L and V337M tau was recognised by
PHF-1 in the absence of GSK-3L. As previous studies have
demonstrated by alkaline phosphatase treatment that the dif-
ferent species of tau seen when expressed in non-neuronal cells
are due to di¡erential phosphorylation [20], we treated CHO
cells, transfected with wild-type tau, with lithium chloride (25
mM) for 4 h. Lithium inhibits GSK-3L and in doing so it
alters tau phosphorylation in neurons and in CHO cells [21^
23]. In CHO cells, the slowest migrating band was not visible
after lithium treatment but two bands remained, including
that co-migrating with tau R406W.
4. Discussion
The accumulation of tau-containing inclusions accompany-
ing diverse neurodegenerative disorders suggests that disrup-
tion of the normal function of this microtubule-associated
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Fig. 3. Microtubule extension length induced by tau variants. The
sum length of microtubule extensions induced by cytochalsin B in
tau-transfected cells was greater in 4- than in 3-repeat tau. The mu-
tations reduce the extension length with the P301L mutation show-
ing the greatest and the R406W mutation the least e¡ect.
Fig. 2. Cytochalasin B induces microtubule extensions in tau-trans-
fected cells. The microtubule arrangements in CHO cells expressing
tau are altered with the appearance of bundles that tend to circum-
navigate the perimeter of the cell (A, B). No di¡erence between
wild-type tau and mutated tau was seen (only P301L data shown).
The addition of cytochalsin B to disrupt the actin cytoskeleton al-
lowed the extension of microtubule bundles into cellular extensions
(C, D).
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protein, and resulting aggregation, is a critical factor in patho-
genesis [9]. However the mechanism whereby this occurs is not
understood. Although progress has been made in demonstrat-
ing that tau in the paired helical ¢laments of AD is highly
phosphorylated, in determining the phosphorylation sites and
in identifying the kinases and phosphatases responsible, it has
proven di⁄cult to determine whether phosphorylation is a
cause or a result of aggregation [2]. Finding mutations in
tau in FTDP-17 o¡ers a unique opportunity to explore further
the sequence of events resulting in the aggregation of tau.
In vitro studies have demonstrated that mutations in tau
reduce but do not abolish the ability of tau to promote micro-
tubule assembly [10,11]. However, the results obtained on the
relative e¡ects of the di¡erent mutations have been contra-
dictory. Hasewaga et al. [10] found only a relatively modest
e¡ect of the R406W mutation and a maximal e¡ect of the
P301L mutation. In contrast, Hong et al. [11] found a max-
imal e¡ect of the R406W mutation and little, if any e¡ect, of
the V337M mutation. The reason for these discrepancies is
currently unclear. We have developed an assay for analyzing
the e¡ect of the FTDP-17 mutants on microtubule formation
in transfected cells. This quantitative assay has the further
advantage that we are also able to observe di¡erences between
4-repeat and 3-repeat tau isoforms in the same system (exon
10 splice site mutants increase the level of 4-repeat tau).
Our ¢ndings are in line with that of the in vitro data pro-
vided by Hasegawa et al. [10] in that the P301L mutation
reduced the microtubule extension length to the greatest ex-
tent followed by the V337M mutation. Furthermore the abil-
ity of 4-repeat tau to induce extensions was considerably
greater than that of 3-repeat tau. We conclude therefore
that the pathogenic mechanism of the FTDP-17 V337M and
P301L missense mutations is likely to involve a partial loss of
the microtubule assembly/binding properties of tau. Neuro-
degeneration might result from this partial loss of function,
leading to altered axonal transport or increased vulnerability
of neurons. Alternatively, it is possible as suggested by Hong
et al. [11] that a toxic gain of function would result from
increased unbound cytoplasmic tau and the subsequent aggre-
gation. The mechanism of the FTDP-17 splice site mutants
[5,6] which increase the proportion of 4-repeat tau remains
unclear, however it is obvious from these experiments that
the 4-repeat and 3-repeat isoforms do di¡er in the properties
they confer to bound microtubules. It is therefore possible
that the alteration in microtubule dynamics, caused by an
increase in 4-repeat tau, is su⁄cient to cause neurodegenera-
tion. Alternatively, the increase in 4-repeat isoforms might
lead to increased levels of unbound cytoplasmic 4-repeat tau
and thus to aggregation.
Our cell-based studies did not ¢nd a signi¢cant e¡ect of the
R406W FTDP-17 mutation with each isoform separately but
a small and signi¢cant e¡ect of combined 3-repeat R406W
and 4-repeat R406W tau compared to combined wild-type
isoforms. A slight decrease in microtubule extensions might
represent a very small loss of function, enough to cause late
onset disease, and this might account for the relatively mild
phenotype in families with this mutation [24]. However, it is
possible that some other factor accounts for the pathogenic
e¡ect of this mutation. To further examine the e¡ect of the
R406W mutation on the properties of tau, we have studied
the e¡ect of the FTDP-17 missense mutations on tau phos-
phorylation.
Phosphorylation regulates the properties of tau principally
tubulin binding and microtubule polymerisation [2,25]. Many
kinases can phosphorylate tau in vitro but increasing evidence
suggests that GSK-3L is the predominant physiological tau
kinase acting alone, or in conjunction with other kinases.
All tau variants, including the FTPD-17 R406W mutation,
were phosphorylated by overexpression of GSK-3L. However,
it was apparent that R406W tau was not completely phos-
phorylated when compared to the other variants and the
phosphorylation of R406W expressed in CHO cells in the
absence of GSK-3L was di¡erent to that of wild-type tau
and to tau bearing other FTDP-17 mutations. The multiple
bands of tau, observed when expressed in non-neuronal cells,
represent di¡erent phosphorylation states [20] and the faster
migrating of the two bands of tau when expressed in CHO
cells aligns with equivalent recombinant tau [12]. As both 3-
repeat and 4-repeat R406W tau only appears as this single
lower band, we conclude that this mutation reduces the phos-
phorylation of tau by endogenous kinases in CHO cells. Fur-
ther evidence for a change in the phosphorylation in the
R406W mutant tau comes from immunoblotting with an anti-
body raised to the closest phosphorylated epitope to the site
of the mutation, PHF-1, recognising an epitope including
phosphorylated Ser-404. [16]. A proportion of tau is phos-
phorylated at the PHF-1 epitope in CHO cells by endogenous
kinases and this is reduced by the R406W mutation, and by
lithium, but not the other mutations. Lithium, an inhibitor of
GSK-3L, also reduces the number of bands recognised by
TP70 from three to two. However GSK-3L is unlikely to be
solely responsible for the phosphorylation changes in R406W
tau as the migration pattern of tau induced by lithium treat-
ment is not identical to the migration pattern of R406W tau.
It is possible that a number of endogenous kinases, including
GSK-3L, are responsible for the phosphorylation changes in-
duced by the mutation and also that sites other than Ser-404
are a¡ected.
To date, the relationship between phosphorylation and tau
interaction with microtubules has been thought to be straight-
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Fig. 4. Phosphorylation of tau variants in CHO cells. Wild-type tau
expressed in CHO cells alone (3) and together (+) with GSK-3 was
examined by Western blotting using the phosphorylation-independ-
ent antibody TP70 and the phosphorylation-dependant antibodies
TAU1, AT8 and PHF-1. The migration pattern of tau was altered
from three TP70 labelled bands by the R406W mutation and to two
bands by lithium. PHF-1 labelling was reduced by the R406W mu-
tation and abolished by lithium.
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forward in that an increase in phosphorylation at one or more
sites decreases the ability of tau to promote microtubules. We
observe a simultaneous decrease in phosphorylation and a
small decrease in microtubule extension. It might be that
this change in phosphorylation renders tau more susceptible
to phosphorylation by other kinases at sites that do not alter
the electrophoretic mobility whilst reducing microtubule bind-
ing ability. Alternatively the relationship between phosphoryl-
ation and microtubule binding ability in tau might be more
complex than hitherto suspected as it is for MAP2c where
both an increase and a decrease in phosphorylation reduces
the ability to promote microtubule elongation [26].
In summary, our results and those of others suggest that
several di¡erent pathogenic mechanisms may result from the
mutations in tau that are associated with FTDP-17. Intronic
mutations lead to an excess of 4-repeat tau which may disrupt
microtubule dynamics or might lead to increased amounts of
cytosolic unbound 4-repeat tau which then aggregates to form
paired helical or straight ¢laments. Mutations in the micro-
tubule binding repeat domains reduce the a⁄nity of tau for
tubulin/microtubules. Finally the R406W mutation may exert
its e¡ect via a phosphorylation-dependent mechanism which
could result in a reduction in microtubule binding and an
excess of free tau or in a direct increase in aggregation.
Clearly, future studies are needed to explore these possibilities
further.
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